Zenapax 25 mg/5 ml Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Zenapax 25 mg/5 ml Injection contains daclizumab, an interleukin-2 receptor antagonist monoclonal antibody. Its labelling describes it for the treatment of multiple sclerosis (MS), a condition in which the immune system attacks the protective sheath around nerves. It is described as suppressing the immune response to reduce nerve inflammation and the risk of disease progression, and is given only by a healthcare professional.
Product Information
The following description reflects information associated with daclizumab and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of multiple sclerosis
- Described as suppressing the immune response that damages the protective sheath around nerves
- Described as reducing nerve inflammation, limiting further nerve damage, and stabilising the immune system
Described Dosage & Administration
- Administered only by a doctor or nurse as an injection — not self-administered
- The doctor’s instructions on how to take it should be followed; if none are given, the label should be read
- The stated dose should not be exceeded, as overdosing is described as causing serious side effects
Described Side Effects
Commonly described side effects include:
- Upper respiratory tract infection and bronchitis
- Flu-like symptoms
- Dermatitis and eczema
- Low or depressed mood
- Injection-site reactions (pain, swelling, redness)
These are described as commonly temporary. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- The doctor should be informed of all other medicines being taken
- The doctor should be told if the recipient is pregnant or breastfeeding
- Full medical records should be shared with the healthcare team before administration
- Any persistent or severe side effect should be reviewed by a clinician
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains daclizumab and is used for the treatment of multiple sclerosis, described as suppressing the immune response that damages the protective sheath around nerves. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a doctor or nurse as an injection. It is not self-administered, and the stated dose should not be exceeded.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.